The Future Promise Of Advanced Therapies In Ophthalmology

By Louis Cicchini, Ph.D., director, scientific affairs, cell & gene therapy, Cencora

Cell and gene therapies (CGTs) in ophthalmology are offering new hope for patients with difficult-to-treat or previously untreatable conditions. Unlike traditional pharmaceuticals that often treat symptoms or delay degenerative processes, CGTs aim to address the underlying causes of diseases, with many having curative intent. For rare genetic diseases like retinitis pigmentosa (RP), gene-replacement therapy can target the mechanism behind this progressive and debilitating condition.

Developers are exploring diverse approaches, including gene-agnostic strategies to boost patient access, different therapeutic agents, and various routes of administration to optimize drug delivery and improve clinical responses. This diversity in approaches and the potential for curative outcomes make CGTs an exciting and promising therapeutic modality in ophthalmology.

Read on to gain deeper insights into the promising future of advanced therapies in ophthalmology and their potential impact on patient care.